| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H18FN3O2 |
| Molecular Weight | 326.3554 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC1=NC=C(C=C1)C2=NC3=CC=C(OC[C@H](O)C[18F])C=C3C=C2
InChI
InChIKey=DLVXFZWSPCOWSN-DHZJDKHOSA-N
InChI=1S/C18H18FN3O2/c1-20-18-7-3-13(10-21-18)17-5-2-12-8-15(4-6-16(12)22-17)24-11-14(23)9-19/h2-8,10,14,23H,9,11H2,1H3,(H,20,21)/t14-/m1/s1/i19-1
18F-THK-5351 is a novel radiotracer that demonstrates high binding selectivity and affinity for tau pathology and exhibits better pharmacokinetics in the living brain than previous THK tau probes. FluoroTau is in phase II clinical trials as a positron emission tomography (PET) imaging agent for the diagnosis and monitoring of the progression of Alzheimer's disease(AD) in South Korea.
This compound was originally discovered by Tohoku University, and now is being developed by GE Healthcare, Samung Medical Centre and Asan Medical Center.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
18F-THK-5351 radiotracer was injected through a venous line into the arm of 12
subjects with a mean administered activity of 377.8 +/-14.0 MBq. The scanning
protocol included 1–2 min emission scans for four cycles at 10, 60, 120, and 240
min post-injection. Each cycle consisted of seven bed positions, thus the
whole-body scanning time was 10 min per cycle.
Route of Administration:
Intravenous
ACTIVE MOIETY
